Compare Stocks: GRCE, SLGL, SBTX, and IMUX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GRCE Grace Therapeutics	$2.23 -2.6%	$2.22	$1.79 ▼ $5.18	$48.17M	0.44	144,187 shs	66,183 shs
IMUX Immunic	$10.37 -7.7%	$14.51	$5.06 ▼ $17.43	$153.23M	1.41	268,774 shs	287,348 shs
SBTX Silverback Therapeutics	$4.50 -5.5%	$6.09	$2.80 ▼ $8.97	$211.66M	0.6	337,931 shs	2.17 million shs
SLGL Sol-Gel Technologies	$64.40 -1.2%	$77.42	$23.15 ▼ $97.97	$183.15M	1.12	58,614 shs	59,130 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GRCE Grace Therapeutics	-2.62%	+5.19%	+3.24%	+0.45%	-27.36%
IMUX Immunic	-7.66%	-18.60%	-35.43%	-26.97%	+34.12%
SBTX Silverback Therapeutics	-5.46%	-19.93%	-20.35%	-53.61%	-55.13%
SLGL Sol-Gel Technologies	-1.20%	-7.16%	-23.96%	-8.47%	+168.84%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GRCE Grace Therapeutics	$2.23 -2.6%	$2.22	$1.79 ▼ $5.18	$48.17M	0.44	144,187 shs	66,183 shs
IMUX Immunic	$10.37 -7.7%	$14.51	$5.06 ▼ $17.43	$153.23M	1.41	268,774 shs	287,348 shs
SBTX Silverback Therapeutics	$4.50 -5.5%	$6.09	$2.80 ▼ $8.97	$211.66M	0.6	337,931 shs	2.17 million shs
SLGL Sol-Gel Technologies	$64.40 -1.2%	$77.42	$23.15 ▼ $97.97	$183.15M	1.12	58,614 shs	59,130 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GRCE Grace Therapeutics	-2.62%	+5.19%	+3.24%	+0.45%	-27.36%
IMUX Immunic	-7.66%	-18.60%	-35.43%	-26.97%	+34.12%
SBTX Silverback Therapeutics	-5.46%	-19.93%	-20.35%	-53.61%	-55.13%
SLGL Sol-Gel Technologies	-1.20%	-7.16%	-23.96%	-8.47%	+168.84%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GRCE Grace Therapeutics	2.00	Hold	$6.00	169.06% Upside
IMUX Immunic	3.00	Buy	$47.25	355.64% Upside
SBTX Silverback Therapeutics	0.00	N/A	N/A	N/A
SLGL Sol-Gel Technologies	2.67	Moderate Buy	$197.50	206.68% Upside

Current Analyst Ratings Breakdown

Latest GRCE, SLGL, SBTX, and IMUX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/10/2026	IMUX Immunic	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$45.00
9/10/2026	IMUX Immunic	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$22.00
9/1/2026	SLGL Sol-Gel Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/1/2026	IMUX Immunic	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/26/2026	IMUX Immunic	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/17/2026	IMUX Immunic	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$45.00
8/3/2026	GRCE Grace Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
7/29/2026	IMUX Immunic	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/20/2026	SLGL Sol-Gel Technologies	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$110.00
7/17/2026	GRCE Grace Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/24/2026	SLGL Sol-Gel Technologies	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$285.00

(Data available from 9/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GRCE Grace Therapeutics	N/A	N/A	N/A	N/A	$3.99 per share	N/A
IMUX Immunic	N/A	N/A	N/A	N/A	($0.55) per share	N/A
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	$7.41 per share	N/A
SLGL Sol-Gel Technologies	$19.39M	9.33	N/A	N/A	$8.19 per share	7.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GRCE Grace Therapeutics	-$7.79M	-$1.18	N/A	N/A	N/A	N/A	-36.11%	-34.39%	11/12/2026 (Estimated)
IMUX Immunic	-$97.17M	-$4.38	N/A	N/A	N/A	N/A	-157.89%	-107.88%	11/12/2026 (Estimated)
SBTX Silverback Therapeutics	-$89.48M	-$2.42	N/A	N/A	N/A	N/A	-29.62%	-28.20%	N/A
SLGL Sol-Gel Technologies	-$6.13M	-$5.64	N/A	N/A	N/A	-910.14%	-44.05%	-36.96%	11/19/2026 (Estimated)

Latest GRCE, SLGL, SBTX, and IMUX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/21/2026	Q2 2026	SLGL Sol-Gel Technologies	-$2.36	-$1.13	+$1.23	-$1.13	$0.08 million	$0.59 million
8/14/2026	Q1 2027	GRCE Grace Therapeutics	-$0.1293	-$0.91	-$0.7807	-$0.91	$0.40 million	N/A
8/11/2026	Q2 2026	IMUX Immunic	-$1.16	-$0.80	+$0.36	-$0.80	N/A	N/A
6/18/2026	Q4 2026	GRCE Grace Therapeutics	-$0.24	-$0.07	+$0.17	-$0.06	$0.90 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GRCE Grace Therapeutics	N/A	N/A	N/A	N/A	N/A
IMUX Immunic	N/A	N/A	N/A	N/A	N/A
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	N/A
SLGL Sol-Gel Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GRCE Grace Therapeutics	N/A	11.47	11.47
IMUX Immunic	N/A	5.05	5.05
SBTX Silverback Therapeutics	N/A	67.87	67.87
SLGL Sol-Gel Technologies	N/A	10.37	10.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GRCE Grace Therapeutics	6.08%
IMUX Immunic	51.82%
SBTX Silverback Therapeutics	74.89%
SLGL Sol-Gel Technologies	26.18%

Insider Ownership

Company	Insider Ownership
GRCE Grace Therapeutics	10.84%
IMUX Immunic	5.49%
SBTX Silverback Therapeutics	34.40%
SLGL Sol-Gel Technologies	66.51%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GRCE Grace Therapeutics	N/A	21.04 million	18.76 million	N/A
IMUX Immunic	95	13.64 million	12.90 million	Optionable
SBTX Silverback Therapeutics	83	36.06 million	23.65 million	Not Optionable
SLGL Sol-Gel Technologies	28	2.81 million	941,000	No Data

GRCE, SLGL, SBTX, and IMUX Headlines

Recent News About These Companies

Opaleye Management Inc. Buys 1,631 Shares of Sol-Gel Technologies (NASDAQ:SLGL) Stock

1 hour ago | americanbankingnews.com

Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Buys $98,448.42 in Stock

September 15 at 4:37 AM | insidertrades.com

Opaleye Management Inc. Buys 1,493 Shares of Sol-Gel Technologies (NASDAQ:SLGL) Stock

September 14 at 7:07 PM | marketbeat.com

Opaleye Management Inc. Acquires 1,631 Shares of Sol-Gel Technologies (NASDAQ:SLGL) Stock

September 14 at 7:07 PM | marketbeat.com

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Given Consensus Recommendation of "Moderate Buy" by Brokerages

September 11, 2026 | americanbankingnews.com

Sol-Gel Technologies: Phase 3 Gorlin Results Could Be The Next Major Catalyst

September 10, 2026 | rttnews.com

Insider Buying: Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Acquires 3,018 Shares

September 10, 2026 | insidertrades.com

Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Opaleye Management Inc. Acquires 3,018 Shares

September 9, 2026 | marketbeat.com

Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Acquires 3,097 Shares

September 9, 2026 | marketbeat.com

Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Opaleye Management Inc. Acquires 3,861 Shares

September 9, 2026 | marketbeat.com

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Given Average Rating of "Moderate Buy" by Brokerages

September 6, 2026 | marketbeat.com

Insider Buying: Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Purchases 5,217 Shares

September 1, 2026 | insidertrades.com

Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Opaleye Management Inc. Acquires 5,217 Shares of Stock

August 31, 2026 | marketbeat.com

Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Buys 35,113 Shares

August 31, 2026 | marketbeat.com

Sol-Gel Technologies Ltd.: Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

August 20, 2026 | finanznachrichten.de

Sol-Gel Technologies (NASDAQ:SLGL) Posts Quarterly Earnings Results, Beats Expectations By $1.23 EPS

August 20, 2026 | marketbeat.com

Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

August 20, 2026 | globenewswire.com

Sol-Gel Technologies Insider Trading Activity | NASDAQ:SLGL | Benzinga

July 23, 2026 | benzinga.com

Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Opaleye Management Inc. Acquires 229 Shares

July 11, 2026 | insidertrades.com

Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Acquires $22,460.88 in Stock

July 3, 2026 | insidertrades.com

Sol-Gel Technologies (SLGL) Initiated with a Buy at Mizuho Securities

June 26, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRCE, SLGL, SBTX, and IMUX Company Descriptions

Grace Therapeutics NASDAQ:GRCE

$2.23 -0.06 (-2.62%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$2.23 0.00 (0.00%)

As of 09/15/2026 07:30 PM Eastern

Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.

Immunic NASDAQ:IMUX

$10.37 -0.86 (-7.66%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$10.97 +0.60 (+5.79%)

As of 06:07 AM Eastern

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Silverback Therapeutics NASDAQ:SBTX

$4.50 -0.26 (-5.46%)

As of 09/14/2026

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Sol-Gel Technologies NASDAQ:SLGL

$64.40 -0.78 (-1.20%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$64.40 -0.01 (-0.01%)

As of 05:10 AM Eastern

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GRCE, SLGL, SBTX, and IMUX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GRCE, SLGL, SBTX, and IMUX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GRCE, SLGL, SBTX, and IMUX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRCE, SLGL, SBTX, and IMUX Company Descriptions

Grace Therapeutics NASDAQ:GRCE

Immunic NASDAQ:IMUX

Silverback Therapeutics NASDAQ:SBTX

Sol-Gel Technologies NASDAQ:SLGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GRCE, SLGL, SBTX, and IMUX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GRCE, SLGL, SBTX, and IMUX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GRCE, SLGL, SBTX, and IMUX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRCE, SLGL, SBTX, and IMUX Company Descriptions

Grace Therapeutics NASDAQ:GRCE

Immunic NASDAQ:IMUX

Silverback Therapeutics NASDAQ:SBTX

Sol-Gel Technologies NASDAQ:SLGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools